Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to < 15 Years
Condition: Dengue Fever Interventions: Biological: 9vHPV vaccine; Biological: Dengue Tetravalent Vaccine (TDV) Sponsor: Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cervical Cancer Vaccine | Dengue Fever | Gardasil | Genital Warts | Human Papillomavirus (HPV) | Research | Vaccines